Listed by the USPTO as MOSS, NATALIE M
Tech Center 1600 • Art Units: 1651 1653
This examiner grants 31% of resolved cases
MOSS, NATALIE M is assigned to Tech Center 1600 and art unit 1651. The profile covers 525 resolved cases, with an allowance rate of 30.7%, a 16.9% interview lift, and a median of 1416 days to allowance. The allowance figure indicates that prosecution outcomes in this record are more often non-allowance than allowance.
Genentech Inc., University of Florida Research Foundation Inc., and The Regents of the University of California are the listed top companies. The listed firms are Casimir Jones, S.C., MARSHALL, GERSTEIN & BORUN LLP, and OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P. The case volume supports using the profile for portfolio planning. The interview measure supports considering interviews, but it does not outweigh the broader allowance pattern.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | Non-Final OA | Genentech, Inc. |
| 17756842 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | Non-Final OA | The University of Florida Research Foundation, Inc. |
| 18227801 | Methods for Antimicrobial Susceptibility Testing | Final Rejection | The Regents of the University of California |
| 17639210 | PRESERVATION OF ORGANS FOR TRANSPLANT AND NON-TRANSPLANT SURGERIES | Final Rejection | The Regents of the University of Michigan |
| 14239690 | PROCESS FOR PRODUCING CELLULASES USING A FILAMENTOUS FUNGUS SUITABLE FOR A FERMENTER, HAVING A LOW VOLUMETRIC OXYGEN TRANSFER COEFFICIENT KLA | Non-Final OA | IFP ENERGIES NOUVELLES |
| 17763723 | CONCENTRATED PERFUSION MEDIUM | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17842762 | FGF-18 IN GRAFT TRANSPLANTATION AND TISSUE ENGINEERING PROCEDURES | Final Rejection | MERCK PATENT GMBH |
| 17439251 | ISOLATION, ENRICHMENT AND EXPANSION OF CONE PROGENITOR CELLS AND USES THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 17213417 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17688516 | USE OF AN EXTRACELLULAR MATRIX (ECM) HYDROGEL AS AN ESOPHAGEAL SUBMUCOSAL FLUID CUSHION | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17879015 | Method of Recovering Nitrogen and Sulfur Resources Through Anaerobic Fermentation | Final Rejection | SK Innovation Co., Ltd. |
| 17906727 | Upregulation of Cathelicidin Gene Expression as an Adjuvant to Other Treatments for Diseases | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17541558 | FASTING MIMICKING KETOGENIC DIET (FMD) TO PROMOTE SKELETAL MUSCLE REGENERATION AND STRENGTH | Final Rejection | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 18601773 | CARDIOSPHERE-DERIVED CELLS AND THEIR EXTRACELLULAR VESICLES FOR TREATMENT AND PREVENTION OF CANCER | Final Rejection | CEDARS-SINAI MEDICAL CENTER |
| 17259784 | INJECTION TECHNIQUES FOR THE TREATMENT OF CELLULITE | Non-Final OA | ENDO OPERATIONS LIMITED |
| 17782801 | COMPOSITION FOR TREATING OR PREVENTING AN ALLERGY OR ALLERGIC REACTION | Final Rejection | Aposcience AG |
| 18277278 | CELL SHEET SUPPORT, CELL SHEET LAMINATE AND METHOD FOR PRODUCING SAME | Final Rejection | FUKUOKA UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy30.7% of resolved applications examined by Natalie M Moss were allowed (525 resolved cases), compared with 31.5% across Art Unit 1651 over the last five years.
This examiner's interview lift is +16.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Natalie M Moss took 1,416 days on average from filing to allowance.
Natalie M Moss examines applications in Art Unit 1651 in Tech Center 1600 (Biotechnology & Pharmaceuticals).